Search

Your search keyword '"Lahuerta, Juan"' showing total 1,318 results

Search Constraints

Start Over You searched for: Author "Lahuerta, Juan" Remove constraint Author: "Lahuerta, Juan"
1,318 results on '"Lahuerta, Juan"'

Search Results

1. Immunoparesis recovery in newly diagnosed transplant ineligible multiple myeloma patients, an independent prognostic factor that complements minimal residual disease

2. Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistance

3. Lenalidomide and dexamethasone maintenance with or without ixazomib, tailored by residual disease status in myeloma

4. Prolonged lenalidomide maintenance therapy improves the depth of response in multiple myeloma

5. The clinical significance of stringent complete response in multiple myeloma is surpassed by minimal residual disease measurements

6. Prognostic Value of Serum Paraprotein Response Kinetics in Patients With Newly Diagnosed Multiple Myeloma

7. Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial

9. Postoperative neurological complications after brachial plexus block: a retrospective study conducted at a teaching hospital

10. FlowCT for the analysis of large immunophenotypic data sets and biomarker discovery in cancer immunology

11. A Simple Frailty Score Predicts Survival and Early Mortality in Systemic AL Amyloidosis

12. Selinexor, daratumumab, bortezomib and dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma: results of the phase II, non-randomized, multicenter GEM-SELIBORDARA study

13. Predictors of unsustained measurable residual disease negativity in transplant-eligible patients with multiple myeloma

14. Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial

15. Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma

17. A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma

18. Unsupervised machine learning improves risk stratification in newly diagnosed multiple myeloma: an analysis of the Spanish Myeloma Group

19. Immunogenetic characterization of clonal plasma cells in systemic light-chain amyloidosis

20. Integrated analysis of randomized controlled trials evaluating bortezomib + lenalidomide + dexamethasone or bortezomib + thalidomide + dexamethasone induction in transplant-eligible newly diagnosed multiple myeloma

21. Autologous stem cell transplantation may be curative for patients with follicular lymphoma with early therapy failure without the need for immunotherapy

22. Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma

23. Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial

24. International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders

25. Lenalidomide and dexamethasone with or without clarithromycin in patients with multiple myeloma ineligible for autologous transplant: a randomized trial

26. P848: EXPRESSION PROFILE OF BCL-2 FAMILY PROTEINS IN MULTIPLE MYELOMA.

28. Flow cytometry for fast screening and automated risk assessment in systemic light-chain amyloidosis

29. Early myeloma-related death in elderly patients: development of a clinical prognostic score and evaluation of response sustainability role

30. Predictors of unsustained measurable residual disease negativity in transplant-eligible patients with multiple myeloma

31. AL Amyloidosis and Multiple Myeloma: A Complex Scenario in Which Cardiac Involvement Remains the Key Prognostic Factor

32. Cost Analysis of Low-Volume Versus Standard-Volume Ultrasound-Guided Interscalene Brachial Plexus Block in Arthroscopic Shoulder Surgery

33. Autologous Stem Cell Transplantation for Follicular Lymphoma: Favorable Long-Term Survival Irrespective of Pretransplantation Rituximab Exposure

34. Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma

35. Multiple myeloma and SARS-CoV-2 infection: clinical characteristics and prognostic factors of inpatient mortality

37. Molecular profiling of immunoglobulin heavy-chain gene rearrangements unveils new potential prognostic markers for multiple myeloma patients

38. Measurable residual disease by mass spectrometry and next-generation flow to assess treatment response in myeloma

39. Secondary malignancies and survival outcomes after autologous stem cell transplantation for follicular lymphoma in the pre-rituximab and rituximab eras: a long-term follow-up analysis from the Spanish GELTAMO registry

40. A predictive model for risk of early grade ≥ 3 infection in patients with multiple myeloma not eligible for transplant: analysis of the FIRST trial

41. Randomized phase II study of weekly carfilzomib 70 mg/m2 and dexamethasone with or without cyclophosphamide in relapsed and/or refractory multiple myeloma patients

42. Supplementary Figure from A Machine Learning Model Based on Tumor and Immune Biomarkers to Predict Undetectable MRD and Survival Outcomes in Multiple Myeloma

45. Supplementary Data from A Machine Learning Model Based on Tumor and Immune Biomarkers to Predict Undetectable MRD and Survival Outcomes in Multiple Myeloma

48. Cell Count Differentials by Cytomorphology and Next-Generation Flow Cytometry in Bone Marrow Aspirate: An Evidence-Based Approach

50. Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistance

Catalog

Books, media, physical & digital resources